替吉奥联合顺铂治疗老年人进展期胃癌

目的 探讨替吉奥联合顺铂治疗老年人进展期胃癌的临床疗效.方法 85例老年进展期胃癌患者根据治疗方案的不同将患者分为观察组(43例)和对照组(42例),观察组给予替吉奥联合顺铂治疗,对照组给予氟尿嘧啶联合顺铂治疗,观察两组临床疗效、不良反应及生存情况.结果 所有患者均完成化疗周期.观察组和对照组有效率分别为67.4％和52.4％,观察组优于对照组(x2=2.491,P＜0.05)；观察组和对照组控制率分别为93.0％和81.0％,观察组优于对组组(x2=2.827.P＜0.05).两组不良反应前三位依次是恶心呕吐、白细胞减少及血红蛋白降低,两组不良反应发生率差异无统计学意义(均P ＞0.05).全部患者均获得全程随访,随访时间(15.5±2.7)个月,观察组1年生存率60.5％(26/43),对照组1年生存率52.4％(21/42),两组差异无统计学意义(x2=1.093,P＞0.05).结论 替吉奥联合顺铂治疗老年人进展期胃癌具有较好的疗效,且其不良反应可以耐受.

Effect of Gimeracil and Oteracil Porassium combined with cisplatin in the treatment of old patients with advanced gastric cancer

Objective To investigate the clinical efficacy of S-1 combined with cisplatin in the treatment of old patients with advanced gastric cancer. Methods 85 patients were randomly divided into two groups. Experimental group was treated by S-1 combined with cisplatin, while control group was treated by 5-FU and cisplatin. Short-term ef- ficacy and adverse reactions were evaluated after four cycles. Results All patients had successfully accomplished chemotherapy. Compared with the control group（ RR = 52.4% , DCR = 81.0% ） , RR and DCR in experimental group （ RR = 67.4% , DCR = 93.0% ） had statistically significant difference（ P 〈 0.05 ）. The top three of adverse reactions and complications in patients of the two groups were ： nausea and vomiting, low WBC, low hemoglobin concentration. Compared with the control group, the toxicity in experimental group had no statistically significant difference （ P 〉 0. 05）. All patients were followed up with a mean of（ 15.5 ± 2.7 ） months. The 1 year survival rate was 60.5% （26/43） in the experimental group;the 1 year survival rate was 52.4% （21/42） in the control group. There was no statistically significant difference （ P 〉 0.05 ）. Conclusion The S-1 combined with cisplatin had shown better efficacy in the treatment of old patients with advanced gastric carcinoma, and the toxicity was relatively mild and tolerable.